{"references": ["Akin, F., Ay\u00e7a, B. and K\u00f6se, N. (2014): Effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia. Angiology. doi: 10.1177/0003319713520419.", "Anderson, J. L. et al. (2007): Usefulness of a Complete Blood Count-Derived Risk Score to Predict Incident Mortality in Patients With Suspected Cardiovascular Disease. American Journal of Cardiology. doi: 10.1016/j.amjcard.2006.08.015.", "Bowles, K. M. et al. (2005): Platelet size has diagnostic predictive value in patients with thrombocytopenia. Clinical and Laboratory Haematology. doi: 10.1111/j.1365- 2257.2005.00726.x.", "Carr, M. C. and Brunzell, J. D. (2004): Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. Journal of Clinical Endocrinology and Metabolism. doi: 10.1210/jc.2004-0432.", "Detwiler, T. C., Odell, T. T. and MacDonald, T. P. (1962): Platelet size, ATP content, and clot retraction in relation to platelet age. The American journal of physiology. doi: 10.1152/ ajplegacy.1962.203.1.107.", "Drachman, J. G. (2004): Inherited thrombocytopenia: When a low platelet count does not mean ITP. Blood. doi: 10.1182/ blood-2003-05-1742.", "Elsayed, A. M., Mohamed, G. A. (2017): Mean platelet volume and mean platelet volume/platelet count ratio as a risk stratification tool in the assessment of severity of acute ischemic stroke. Alexandria Journal of Medicine. doi: 10.1016/j. ajme.2016.03.003.", "Ensign, W., Hill, N., Heward, C. B. (2006): Disparate LDL phenotypic classification among 4 different methods assesing LDL particle characteristics. Clinical Chemistry. doi: 10.1373/ clinchem.2005.059949.", "F\u00e1bryov\u00e1, \u013d. (2016): Aterog\u00e9nna dyslipid\u00e9mia \u2013 nov\u00fd cie\u013e v kardiovaskul\u00e1rnej prevencii. Atheroreview, 1(3), pp. 126\u2013137.", "Ji, S. et al. (2019): Effects of statin therapy on mean platelet volume in patients with risk of cardiovascular diseases: A systematic review and meta-analysis. Bioscience Reports. doi: 10.1042/BSR20190180.", "Ku\u010dera, M. (2019): V\u00fdznam hematologick\u00fdch markerov z poh\u013eadu kardiovaskul\u00e1rneho rizika. Vaskul\u00e1rna Medic\u00edna, 11(2), pp. 70\u201373.", "Lee, Y. M. et al. (2010): Cyclic nucleotides and mitogen-activated protein kinases: Regulation of simvastatin in platelet activation. Journal of Biomedical Science. doi: 10.1186/1423- 0127-17-45.", "Li, J. J. et al. (2012): Impact of 10mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers. Clinica Chimica Acta. doi: 10.1016/j.cca.2011.09.006.", "Lippi, G. et al. (2013): Association of red blood cell distribution width with plasma lipids in a general population of unselected outpatients. Kardiologia Polska. doi: 10.5603/KP. 2013.0228.", "Luzak, B. et al. (2012): Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition. European Journal of Clinical Investigation. doi: 10.1111/ j.1365-2362.2012.02661.x", "Ma, L. P. et al. (2002): Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia. Journal of the Association for Academic Minority Physicians: the official publication of the Association for Academic Minority Physicians", "Mahajan, K. (2015): Microparticles in Atherosclerosis: Biomarkers of Disease (2014). Journal of Clinical & Experimental Cardiology. doi: 10.4172/2155-9880.1000356.", "Maru, A. M. and Kokani, M. J. B. (2018): A study of correlation between Platelet Volume Indices (PVI) in patients of Dyslipidemia in tertiary care hospital. Tropical Journal of Pathology and Microbiology. doi: 10.17511/jopm.2018.i04.03.", "Mat\u00fd\u0161kov\u00e1, M., Bourkov\u00e1, L. and Hoblov\u00e1, J. (2005): Zaji\u0161t\u011bn\u00ed spolehlivosti vy\u0161et\u0159en\u00ed krevn\u00edch obraz\u016f. Vnitrni Lekarstvi.", "May, J. E. et al. (2019): Three neglected numbers in the CBC: The RDW, MPV, and NRBC count. Cleveland Clinic Journal of Medicine. doi: 10.3949/ccjm.86a.18072.", "Moscard\u00f3, A. et al. (2013): Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: Biochemical regulatory mechanisms. Thrombosis Research. doi: 10.1016/j.thromres.2013.01.007", "Oravec, S.; Jedin\u00e1, V.; \u017dit\u0148anov\u00e1, I.; Gruber, K.; Dostal, E. (2020): Mal\u00e9 denzn\u00e9 LDL u os\u00f4b s poruchou metabolizmu lipoprote\u00ednov. Laborat\u00f3rna diagnostika, 25(2), pp. 43\u20134", "Patel, K. V. et al. (2013): Association of the red cell distribution width with red blood cell deformability. Advances in Experimental Medicine and Biology. doi: 10.1007/978-1- 4614-4989-8_29.", "Pedrazzani, C. et al. (2020): Prognostic value of red cell distribution width (RDW) in colorectal cancer. Results from a single-center cohort on 591 patients. Scientific Reports. doi: 10.1038/s41598-020-57721-4.", "Piepoli, M. F. et al. (2016): 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. Oxford University Press, pp. 2315\u20132381. doi: 10.1093/eurheartj/ehw106.", "Santilli, F. et al. (2012): Platelet activation in obesity and metabolic syndrome. Obesity Reviews. doi: 10.1111/j.1467- 789X.2011.00930.x", "Sivri, N. et al. (2013): Statins decrease mean platelet volume irrespective of cholesterol lowering effect. Kardiologia Polska. doi: 10.5603/KP2013.0259", "Vestn\u00edk MZ SR (2015): Odborn\u00e9 usmernenie Ministerstva zdravotn\u00edctva Slovenskej republiky na poskytovanie zdravotnej starostlivosti dospel\u00fdm pacientom s dyslipid\u00e9miou v ambulantnej zdravotnej starostlivosti. Vestn\u00edk Ministerstva zdravotn\u00edctva Slovenskej republiky, \u010diastka 14\u201330, ro\u010dn\u00edk 63."]}

SÚHRN Kvantitatívne a kvalitatívne zmeny lipoproteínov v plazme v prospech aterogénnych častíc významne ovplyvňujú kardiovaskulárne (KV) riziko. Cieľom prezentovanej práce bolo objasniť súvislosť lipoproteínových subpopulácií vo vzťahu k strednému objemu trombocytov (MPV) a k distribučnej šírke erytrocytov (RDW). Vyšetrili sme 80 pacientov s dyslipidémiou (z toho 58 žien, priemerný vek súboru 61 rokov), bez predchádzajúcej hypolipemickej liečby. Liečení boli atorvastatínom 40 mg počas troch mesiacov. Pred liečbou a po 12 týždňoch liečby bol vyšetrený celkový cholesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), triacylglyceroly (TAG), LDL-subfrakcie (veľké LDL častice 1–2 a malé denzné (sd)-LDL častice 3–7), apolipoproteíny (apoA1, apoB), pomer apoB/apoA1, aterogénny index plazmy (AIP), hematologické parametre (vrátane MPV, RDW) a bezpečnostné parametre (obličkové, pečeňové). Hematologické parametre (MPV a RDW) na začiatku liečby signifikantne korelovali s aterogénnymi ukazovateľmi (LDL 3–7, ApoB, ApoB/ApoA1, AIP. Po dvanástich týždňoch atorvastatínovej liečby hladiny MPV a RDW signifikantne klesli súbežne s hladinami lipidov, pričom v skupine s najvýznamnejším poklesom aterogénnych lipoproteínov poklesli tiež. Možno predpokladať, že hladiny MPV a RDW odrážajú proaterogénny lipoproteínový profil reprezentovaný prítomnosťou malých denzných LDL častíc. ABSTRACT Quantitative and qualitative changes in plasma lipoproteins mainly atherogenic particles can significantly affect the cardiovascular risk. The aim of the present study was to analyze the relation of lipoprotein subpopulations to mean platelet volume (MPV) and erythrocyte distribution width (RDW). Patients (n = 80) with dyslipidemia (58 females, mean age 61 years), without previous hypolipemic treatment, were treated with atorvastatin 40 mg/day for 3 months. Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density cholesterol (HDL-C), triglycerides (TAG), LDL-C sub-fractions [large LDL-C 1—2 and small dense (sd)-LDL-C 3—7], apolipoproteins (apoA1, apoB), apoB/apoA1 ratio, atherogenic index of plasma (AIP), haematological parameters (including MPV, RDW) and safety parameters (renal, hepatic) were measured before and after 12 weeks of atorvastatin treatment. Haematological parameters (MPV and RDW) at the baseline of treatment significantly correlated with atherogenic markers (LDL 3—7, ApoB, ApoB/ApoA1, AIP). After 12 weeks of treatment with atorvastatin, MPV and RDW values underwent significant modification simultaneously with other lipids and also in those patients displaying the strongest atherogenic-lowering effect. Values of MPV and RDW seem to reflect a pro-atherogenic lipoprotein profile mainly represented by the presence of sd-LDL-C.